A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE

Figure 8

The MEK inhibitor PD-184352 was found and verified as a potential drug to reverse nonresponse to TACE. (a) Compounds predicted by CMap could produce opposite responses to those in the high-risk group in GSE14520. The -axis shows the categories of the compounds, and the -axis shows compound names. (b) Schematic diagram of the HIF-1 signaling pathway. (c) IC₅₀ of PD-184352 in Hep G2 was detected in a hypoxic environment. (d) Cell proliferation using lobaplatin at cell-specific IC₅₀, PD-184352 at cell-specific IC₅₀, or both was measured in a simulated TACE environment in vitro.

(a)

(b)

(c)

(d)